The recall of certain Chantix lots after the discovery of elevated levels of nitrosamines—chemicals linked to increased cancer risk with long-term exposure—has unsettled many patients who relied on the medication to quit smoking. While the news can feel alarming, the FDA’s swift action and the manufacturer’s cooperation show how safety monitoring systems are meant to detect and address potential risks. Health officials advise patients not to stop treatment suddenly but to consult their doctors about alternatives, such as nicotine replacement therapies, other prescriptions, or counseling. Though disruptive, the recall is part of ensuring patient safety and maintaining trust in the medication review process.